The Federal Circuit cites to case law such as its own 2007 decision in Pfizer, Inc. v. Apotex, Inc. to conclude that “a court is never bound by an examiner’s finding in an ex parte patent application proceeding.” While the findings of the USPTO in reexamination proceedings may be considered evidence, …
